Lorlatinib (Lorviqua) is a third-generation ALK inhibitor that has demonstrated favorable efficacy in the treatment of ALK-positive non-small cell lung cancer (NSCLC). To ensure treatment effectiveness, healthcare providers must fully grasp its medication precautions and monitoring requirements.
What Are the Medication Precautions for Lorlatinib (Lorviqua)?
Dosage Management
The standard recommended dose of lorlatinib is 100 mg orally once daily, with administration at a fixed time each day.
If a dose is missed, it can be taken immediately if more than 4 hours remain before the next scheduled dose; if less than 4 hours remain, the missed dose should be skipped.
If vomiting occurs after taking the medication, no additional dose is needed, and subsequent doses should be continued as originally planned.
The tablets must be swallowed whole and must not be chewed, crushed, or split.
Contraindicated Concomitant Medications
Concurrent use with strong CYP3A inducers is strictly prohibited, as this may lead to severe hepatotoxic reactions.
Lorlatinib treatment can only be initiated after discontinuing strong inducers for 3 half-lives.
Cautions for Concomitant Use
Concomitant use with moderate CYP3A inducers may cause a decrease in blood drug concentration; if co-administration is unavoidable, the dose should be increased to 125 mg once daily.
When used with strong CYP3A inhibitors, the initial dose needs to be reduced from 100 mg to 75 mg once daily.
For patients who have already had their dose reduced to 75 mg due to adverse reactions, further dose reduction to 50 mg is required when initiating strong inhibitors.
Pregnant Patients
Based on animal experimental evidence, lorlatinib has a definite teratogenic risk to the fetus.
Women of childbearing potential must use effective non-hormonal contraceptive measures during treatment and for at least 6 months after the last dose.
Medication Monitoring for Lorlatinib (Lorviqua)
Central Nervous System (CNS) Reaction Monitoring
More than half of patients receiving treatment may experience CNS-related reactions.
These include cognitive dysfunction (memory decline, inattention), mood swings (depressive tendencies, suicidal ideation), speech disorders, and sleep abnormalities, among others.
Clinically, close observation of the patient's mental state is required. Immediate intervention is necessary for those with severe psychiatric symptoms, and measures such as dose interruption, reduction, or permanent discontinuation should be adopted based on the severity.
Blood Lipid Monitoring
Baseline cholesterol and triglyceride levels should be measured before treatment, and re-examination must be conducted 1 and 2 months after initiating treatment, followed by regular monitoring thereafter.
Most patients require concurrent use of lipid-lowering drugs, and dose adjustments of lipid-lowering agents may be necessary when appropriate.
Blood Glucose Monitoring
Fasting blood glucose should be regularly measured before and during treatment.
For patients with grade 3 hyperglycemia or those with poorly controlled blood glucose despite optimized antihyperglycemic therapy, drug administration should be suspended until blood glucose reaches the target level, and dose reduction may be considered subsequently.
Blood Pressure Monitoring
Blood pressure should be stabilized before initiating treatment, and blood pressure changes should be monitored 2 weeks after medication initiation and monthly thereafter.
If grade 3 or higher hypertension occurs, medication should be suspended, and treatment can be resumed at the original or reduced dose after blood pressure returns to normal.
